Skip to Main Content
Center for Cancer ResearchCCR Home | About CCR | CCR Intranet

Headline Title

Pharmacology and Experimental Therapeutics Section and Genetic Tumor Predisposition Program: Staff

Holly Meany, MD

A photo of Holly Meany, MD
Holly Meany, MD

Dr Meany received her MD from Ohio State University College of Medicine and Public Health in Columbus, OH and completed her pediatric residency at Nationwide Children’s Hospital in Columbus and pediatric hematology/oncology fellowship at Children’s National Medical Center in Washington, DC. She joined the PET section in 2004 and her research has focused on the development of new agents for pediatric solid tumors and clinical trial design. She has developed and validated both pharmacokinetic and pharmacodynamic assays as part of active clinical treatment protocols. Dr Meany has a particular interest in neuroblastoma and is currently developing a phase 1 study of a new radio-labeled agent to be used in the treatment of this disease for high risk patients. Dr. Meany is a faculty member in the Division of Oncology at Children’s National Medical Center and continues to collaborate with the PET Section through a grant-funded position.

Dashed Line

return to the top

This Page Last Reviewed on February 26, 2013

About CCR | Clinical Trials | Research | Employment | Initiatives | News | Events | Site Privacy Policy | Accessibility

A Service of the National Cancer Institute

Department of Health and Human Services National Institutes of Health (NIH) USA Gov